86555-45-5

Basic information

• Product Name: (S)-dimethyl 2-benzamidosuccinate
• Synonyms: (S)-dimethyl 2-benzamidosuccinate
• CAS NO: 86555-45-5
• Molecular Formula: C₁₃H₁₅NO₅
• Molecular Weight: 265.2619
• Mol File: 86555-45-5.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-dimethyl 2-benzamidosuccinate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-dimethyl 2-benzamidosuccinate(86555-45-5)
• EPA Substance Registry System: (S)-dimethyl 2-benzamidosuccinate(86555-45-5)

Safety Data

• Hazardous Substances Data: 86555-45-5(Hazardous Substances Data)

Usage

General Description

(S)-dimethyl 2-benzamidosuccinate, also known as DMBS, is a chemical compound that belongs to the family of benzamido succinate derivatives. It is a chiral molecule with two stereoisomers, (R)-DMBS and (S)-DMBS, with the latter being the subject of interest for its potential pharmaceutical applications. (S)-DMBS has been studied for its potential as a chiral ligand in asymmetric synthesis and as a building block in the synthesis of various bioactive compounds. It has also been explored for its potential as an inhibitor of enzymes involved in various biological processes, making it a promising candidate for drug discovery and development. The compound has been synthesized and characterized for its structural and stereochemical properties and continues to be the subject of research for its potential applications in the pharmaceutical and chemical industries.

Upstream product

• 186581-53-3 diazomethane 
• 17966-68-6 N-benzoylaspartic acid 
• 67-56-1 methanol 
• 74-88-4 methyl iodide 
• 135789-87-6 phosphonic acid diethyl ester 
• 714222-57-8 (+/-)-α,β-dimethyl N-benzoyl-α-formylaspartate 
• 74761-86-7 Methyl N^α,N^ε-dibenzoyl-2-vinyllysinate 
• 40149-67-5 dimethyl aspartate 
• 98-88-4 benzoyl chloride 
• 55-21-0 benzamide 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 32213-95-9 dimethyl L-aspartate hydrochloride 
• 6384-18-5 L-Aspartic acid dimethyl ester 
• 39741-26-9 N-benzoyl-L-aspartic acid β-methyl ester 

Downstream Products

• 252580-08-8 (4S,5S)-2-phenyloxazoline-4,5-dicarboxylic acid dimethyl ester 
• 152495-79-9 (S)-3-benzoylamino-tetrahydrofuran 
• 478541-07-0 2-(5-methoxy-2-phenyl-oxazol-4-yl)-acetic acid methyl ester 
• 252580-10-2 L-(2S,3S)-N-benzoyl-3-hydroxyaspartic acid dimethyl ester 
• 15926-44-0 2-phenyl-oxazole-4,5-dicarboxylic acid 
• 144946-64-5 2-phenyl-oxazole-4,5-dicarboxylic acid dimethyl ester 

Relevant articles and documents

Microwave-Assisted Ruthenium-Catalysed ortho-C?H Functionalization of N-Benzoyl α-Amino Ester Derivatives

A microwave-assisted highly efficient intermolecular C?H functionalization sequence has been developed to access substituted isoquinolones using α-amino acid esters as a directing group. This methodology enables a wide range of N-benzoyl α-amino ester derivatives to react via a Ru-catalysed C?H bond activation sequence, to form isoquinolones with moderate to excellent yields. As an additional advantage, our strategy proved to be widely applicable and also enabled the reaction of alkenes to provide access to alkenylated benzamides. The methodology was also extended towards the synthesis of isoquinoline alkaloids derivatives viz. oxyavicine and a dipeptide. The developed protocol is simple and cheap, avoids tedious workup procedures and works efficiently under MW irradiation. (Figure presented.).

POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE

Compounds, compositions, and methods for the treatment of Canavan disease are described.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.